Parkinson’s disease is a chronic, progressive central nervous system disorder that affects 1% of the elderly above 65 years of age and the incidence increases with age. Due to the aging population and the increase in life expectancy the number of patients with Parkinson’s disease will rise in coming years. Parkinson’s does not only present in elderly patients, the first signs develop in many patients while they are still part of the working community.
The disease features a characteristic disturbance in movement and frequently presents with neuropsychiatric (depression) and cognitive (dementia) problems. At the moment there is no cure for Parkinson’s disease.
Due to the many genetic and environmental factors that play a role in the development of the disease and the heterogeneity of the signs and symptoms research by large groups of patients is essential.
With this collaboration we hope to gain more insight into the course of the disease and the development of the specific symptoms of Parkinson’s disease, especially the neuropsychiatric and cognitive disturbances, with the ultimate aim of improved and more targeted treatment. This collaboration will create a large cohort of clinical data and human biomaterial that would not have been possible for one UMC working alone. Furthermore patients have been directly involved in the study design via the Parkinson Society and have into what is to be researched.